Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Asset Writedowns and Impairment (2016 - 2025)

Haemonetics (HAE) has 12 years of Asset Writedowns and Impairment data on record, last reported at $9.3 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $9.3 million; the TTM value through Dec 2025 reached $17.9 million, up 3386.16%, while the annual FY2025 figure was $2.4 million, 77.05% down from the prior year.
  • Asset Writedowns and Impairment reached $9.3 million in Q4 2025 per HAE's latest filing, up from $8.6 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $20.9 million in Q2 2021 and bottomed at $94000.0 in Q3 2022.
  • Average Asset Writedowns and Impairment over 4 years is $6.8 million, with a median of $5.1 million recorded in 2021.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 1046950.0% in 2021, then tumbled 98.17% in 2022.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $5.1 million in 2021, then crashed by 98.17% to $94000.0 in 2022, then skyrocketed by 445.74% to $513000.0 in 2023, then surged by 1712.87% to $9.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $9.3 million in Q4 2025, $8.6 million in Q3 2025, and $513000.0 in Q2 2023.